U.S. markets closed
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • Dow 30

    33,874.24
    -71.34 (-0.21%)
     
  • Nasdaq

    14,271.73
    +18.46 (+0.13%)
     
  • Russell 2000

    2,303.47
    +7.52 (+0.33%)
     
  • Crude Oil

    73.26
    +0.18 (+0.25%)
     
  • Gold

    1,777.00
    -6.40 (-0.36%)
     
  • Silver

    25.89
    -0.22 (-0.85%)
     
  • EUR/USD

    1.1933
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • GBP/USD

    1.3965
    +0.0002 (+0.01%)
     
  • USD/JPY

    110.9770
    +0.0150 (+0.01%)
     
  • BTC-USD

    33,504.80
    +1,086.38 (+3.35%)
     
  • CMC Crypto 200

    800.68
    -9.51 (-1.17%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

CLASS ACTION UPDATE for CYDY, FGEN and CAN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CYDY Shareholders Click Here: https://www.zlk.com/pslra-1/cytodyn-inc-loss-submission-form?prid=15744&wire=1
FGEN Shareholders Click Here: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=15744&wire=1
CAN Shareholders Click Here: https://www.zlk.com/pslra-1/canaan-inc-loss-submission-form?prid=15744&wire=1

* ADDITIONAL INFORMATION BELOW *

CytoDyn Inc. (OTCMKT:CYDY)

CYDY Lawsuit on behalf of: investors who purchased March 27, 2020 - March 9, 2021
Lead Plaintiff Deadline : May 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cytodyn-inc-loss-submission-form?prid=15744&wire=1

According to the filed complaint, during the class period, CytoDyn Inc. made materially false and/or misleading statements and/or failed to disclose that: CytoDyn securities were actively traded over the counter (OTC) in the United States. While the exact number of Class members is unknown to Plaintiff at this time and can be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds or thousands of members in the proposed Class. Record owners and other members of the Class may be identified from records maintained by CytoDyn or its transfer agent and/or OTC Markets and may be notified of the pendency of this action by mail, using the form of notice similar to that customarily used in securities class actions.

FibroGen, Inc. (NASDAQ:FGEN)

FGEN Lawsuit on behalf of: investors who purchased October 18, 2017 - April 6, 2021
Lead Plaintiff Deadline : June 11, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=15744&wire=1

According to the filed complaint, during the class period, FibroGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Canaan Inc. (NASDAQ:CAN)

CAN Lawsuit on behalf of: investors who purchased February 10, 2021 - April 9, 2021
Lead Plaintiff Deadline : June 14, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/canaan-inc-loss-submission-form?prid=15744&wire=1

According to the filed complaint, during the class period, Canaan Inc. made materially false and/or misleading statements and/or failed to disclose that: they concealed that due to ongoing supply chain disruptions and the introduction of the Company's next-generation A12 series bitcoin mining machines - which had cannibalized sales of the older product offerings - Canaan's 4Q20 sales had declined more than 93% year-over-year compared to its fourth quarter fiscal year 2019 ("4Q19") sales and more than 93% quarter-over-quarter compared to its third quarter FY20 ("3Q20") sales.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/646740/CLASS-ACTION-UPDATE-for-CYDY-FGEN-and-CAN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders